The 2025 ophthalmic drugs market size is estimated at USD 17.30 billion, and it is projected to grow at the rate of 7.60% between 2026 and 2035 to USD 18.61 billion and up to USD 33.51 billion, respectively.
US Ophthalmic Drugs Market Revenue and Trends
The US market for ophthalmic drugs provides prescription and over-the-counter medications—including anti-VEGF agents, corticosteroids, NSAIDs, antihistamines/mast cell stabilizers, antibiotics, glaucoma therapies (prostaglandin analogs, beta-blockers, rho kinase inhibitors, and carbonic anhydrase inhibitors), dry eye treatments (cyclosporine, lifitegrast, and artificial tears), and emerging gene/cell therapies—for the treatment of retinal disorders (wet AMD, diabetic macular edema, and retinal vein occlusion), glaucoma, dry eye disease, allergic conjunctivitis, infectious/inflammatory conditions, and post-surgical care.
The US ophthalmic drugs market is growing rapidly due to increasing prevalence of age-related macular degeneration, diabetic retinopathy, glaucoma, and dry eye disease, rising diabetes rates, an aging population, expanded insurance coverage for high-cost biologics, and advancements in sustained-release formulations, preservative-free drops, and novel mechanisms (ROCK inhibitors and gene therapies) in ophthalmology ecosystems.
.png)
What are the Factors That Have a Significant Contribution to the Growth of the US ophthalmic drugs market?
The increase in retinal pathology and chronic ocular surface diseases which are vision-threatening due to the rise in diabetes cases and longer lifespan, longer screen time, environmental influences, and so on, has increased the demand for ophthalmic drugs. With the rising rates of early diagnosis by mass screening campaigns and increased numbers of patients needing long-term glaucoma and dry eye care, the number of prescriptions being filled on branded biologics and cost-effective generics/biosimilars is increasing.
New technologies have brought new innovations such as intravitreal sustained-release implants (dexamethasone, fluocinolone), bimatoprost intracameral implants, preservative-free, multi-dose bottles, cyclosporine/lifitegrast combination therapy, and experimental gene therapies of inherited retinal dystrophies, which are better efficacy, less treatment burden, and improved adherence. Other enabling factors are the strong coverage of anti-VEGF and glaucoma therapies by Medicare Part B and commercial payers, more direct-to-consumer advertising of dry eye and allergy products, the expansion of specialty pharmacy distribution of high-cost injectables, the approval of novel mechanisms by the FDA and a robust pipeline in geographic atrophy, dry AMD and ocular surface regeneration.
Segment Insight
By Product Type
By products, anti-VEGF therapies (ranibizumab, aflibercept, faricimab, and off-label bevacizumab) held by far the largest share of the US ophthalmic drugs market as of 2025, driven primarily by high treatment volumes in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion for their proven ability to preserve vision and delay progression, with continued innovation in longer-acting formulations, bispecific antibodies, and biosimilar anti-VEGF agents cited by large numbers of retina specialists as superior tools for reducing injection frequency and improving real-world patient outcomes.
By Distribution Channel
The largest market share exists amongst specialty pharmacies and retail pharmacies with specialty divisions, which serve as primary channels for dispensing high-cost injectable anti-VEGF agents, glaucoma combination drops, and chronic dry eye therapies. Since these channels provide professional expertise for patient assistance programs, prior authorization support, cold-chain handling, injection training (for home use where applicable), and adherence coaching, they have become preferred options for distributing ophthalmic drugs.
Report Scope
Feature of the Report | Details |
Market Size in 2026 | USD 18.61 billion |
Projected Market Size in 2035 | USD 33.51 billion |
Market Size in 2025 | USD 17.30 billion |
CAGR Growth Rate | 7.60% CAGR |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Key Segment | By Drug Class, Indication, Route of Administration, Distribution Channel and Region |
Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Recent Developments
In November 2025: Apellis Pharmaceuticals was granted wider labeling and higher payer coverage of pegcetacoplan (Syfovre) in geographic atrophy secondary to dry AMD with the real-world evidence showing slower lesion progression and preservation of vision; pegcetacoplan became widely disseminated among retina specialists across the country.
List of the prominent players in the US Ophthalmic Drugs Market:
Regeneron Pharmaceuticals Inc.
Novartis AG (Alcon)
Bausch Health Companies Inc.
AbbVie Inc.
Merck & Co. Inc.
Pfizer Inc.
Johnson & Johnson
Santen Pharmaceutical Co. Ltd.
Coherus BioSciences Inc.
Genentech (Roche)
Others
The US Ophthalmic Drugs Market is segmented as follows:
By Drug Class
Anti-VEGF Agents
o Ranibizumab
o Aflibercept
o Brolucizumab
o Faricimab
Anti-Inflammatory Drugs
o Corticosteroids
o NSAIDs
o Immunomodulators
Anti-Glaucoma Drugs
o Prostaglandin Analogs
o Beta-Blockers
o Alpha-Agonists
o Carbonic Anhydrase Inhibitors
Anti-Infectives
o Antibiotics
o Antivirals
o Antifungals
Other Drug Classes
o Mydriatics/Cycloplegics
o Anti-Allergy Agents
By Indication
Retinal Disorders
o Age-Related Macular Degeneration
o Diabetic Retinopathy
o Diabetic Macular Edema
Glaucoma
Dry Eye Disease
Eye Infections
Other Indications
By Route of Administration
Topical
Intravitreal
Other Routes
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
